Asset profile
Tonlamarsen
RNA / oligonucleotide
Evidence outlook · lead readout
KARDINAL (NCT06864104) · Hypertension
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
KARDINAL (NCT06864104): The study randomized 206 participants to tonlamarsen or placebo with participants, care providers, investigators, and outcome assessors masked. Its primary outcomes were changes in plasma angiotensinogen. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 36 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tonlamarsen: this drug | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| Zilebesiran | Phase 3 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| IBI3016 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| ION904 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| ADX-850 | Phase 1 | RNA / oligonucleotide | Angiotensinogen (AGT) | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Nitric Oxide (INOmax) | Approved | Gas (inhaled) | Nitric oxide | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Treprostinil (Orenitram / Remodulin / Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | ||
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| AJU-C52 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.